Reata Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Autosomal…
Reata Pharmaceuticals, Inc. announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to bardoxolone methyl (bardoxolone) for the treatment of…
Read More...
Read More...
